Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 [Yahoo! Finance]
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
Kymera Therapeutics (NASDAQ:KYMR) was given a new $80.00 price target on by analysts at Truist Financial Corporation.
Kymera Therapeutics (NASDAQ:KYMR) was given a new $90.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader